FDA, Indivior Say Braeburn Fibbing In Opioid Exclusivity Suit
The U.S. Food and Drug Administration and Indivior Inc. are accusing Braeburn Inc. of exaggerating the science behind its opioid-addiction drug Brixadi in hopes of starting sales that are blocked by...To view the full article, register now.
Already a subscriber? Click here to view full article